Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3‐kinase dual inhibitor
Open Access
- 19 May 2017
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 108 (7) , 1469-1475
Abstract
Histone deacetylase ( HDAC )/phosphatidylinositol 3‐kinase ( PI 3K) dual inhibition is a promising strategy for the treatment of intractable cancers because of the advantages of overcoming potential resistance and showing synergistic effects. Therefore, development of an HDAC / PI 3K dual inhibitor is reasonably attractive. Romidepsin ( FK 228, depsipeptide) is a potent HDAC inhibitor. We previously reported that depsipeptide and its analogs have an additional activity as PI 3K inhibitors and are defined as HDAC / PI 3K dual inhibitors. Subsequently, we identified FK ‐A11 as the most potent analog and reported its biochemical, biological, and structural properties as an HDAC / PI 3K dual inhibitor. In this study, we reveal the in vitro and in vivo efficacy of FK ‐A11 in HT 1080 fibrosarcoma and PC 3 prostate cancer cell xenograft mouse models. FK ‐A11 showed in vivo antitumor activity by both i.v. and i.p. administration in a dose‐dependent manner. In both xenograft models, FK ‐A11 showed superior antitumor effects compared to other depsipeptide analogs in accordance with in vitro anti‐cell proliferation effects and the potency of HDAC / PI 3K dual inhibition. In addition, we showed evidence of HDAC / PI 3K dual inhibition accompanying antitumor efficacy in xenograft tumor tissues by immunohistochemistry. We also detailed pharmacokinetic characterization of FK ‐A11 in mice. These findings will be essential for guiding further preclinical and clinical studies.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP895178)
- Japan Agency for Medical Research and Development
This publication has 32 references indexed in Scilit:
- HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven MedulloblastomaCancer Cell, 2016
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2014
- EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC InhibitionCancer Research, 2013
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome ResistanceOncotarget, 2012
- Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase SignalingClinical Cancer Research, 2012
- Advances in Development of Phosphatidylinositol 3-Kinase InhibitorsCurrent Medicinal Chemistry, 2009
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant CancersCancer Research, 2009
- Phosphatidylinositol 3‐kinase inhibitors: promising drug candidates for cancer therapyCancer Science, 2008
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- PHOSPHOINOSITIDE KINASESAnnual Review of Biochemistry, 1998